Please assess the completion status of the following clinical trial:

Trial Title: BRIEF Bendamustine and Rituximab In Elderly Follicular

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed follicular lymphoma CD20+, all grades except the grade 3b with a lymph node biopsy performed within 6 months before study entry and with material available for central review~* A minimal initial immunology is required, including : CD20, bcl-2, CD10 and CD5~* Age must be ≥ 60 years~* Patients not previously treated~* Patients with an intermediate or high risk FLIPI score requiring 2 or more of the following adverse prognostic factors:~  1. Age \>60 ans~ 2. Ann Arbor Stage (III-IV vs. I-II)~ 3. Hemoglobin level ( \< 12g/dL vs. ≥ 12 g/dL)~ 4. Number of nodal areas (\< 5 vs. ≥ 5) (Note: LDH should not be considered as an adverse prognostic factor in this study since it is considered as high tumor burden in the GELF criteria)~* Low burden disease at study entry according to the GELF criteria~* Patients with at least one measurable site of disease: patients with only blood or marrow or splenic infiltration are excluded~* Performance status ≤ 2 on the ECOG scale~* Adequate hematological function (unless abnormalities are related to lymphoma infiltration of the bone marrow) including:~* Hemoglobin ≥ 8.0 g/dL (5.0 mmol/L)~* Absolute neutrophil count (ANC) ≥ 1.5 x 109/L~* Platelet count ≥ 100 x 109/L~* Adequate renal function: calculated creatinine clearance \> 50 ml/min (according to MDRD method) unless these abnormalities are related to lymphoma~* Adequate hepatic function: Total bilirubin \< 2.0 mg/dl (34 µmol/L), AST (SGOT) and ALT (SGPT) ≤ 2.5 x the upper limit of normal unless these abnormalities are related to lymphoma~* Adequate cardiac function: LEVF ≥ 50% calculated by echocardiography or scintigraphy~* Having previously signed a written informed consent~Exclusion Criteria:~* Other histological types of lymphoma than follicular lymphoma~* Grade 3b follicular lymphoma~* Patients previously on watch and wait since more than 6 months from diagnosis~* Patients previously treated for lymphoma, except splenectomy~* Patients with low FLIPI score (0 or 1 adverse prognostic factors not considering elevated LDH)~* Bulky disease at study entry according to the GELF criteria~* Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningitis)~* Patients with prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer or previous cancer in CR without any treatment in the last 5 years~* Positive HIV, HBV (anti-HBc positivity) and HCV serologies before inclusion~* Poor Performance status \> 2 on the ECOG scale~* Known contra-indication to study product~* Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease).~* Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give informed consent.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab + bendamustine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy